Rivian partners with VW, stock is up big

What you need to know                                                                                                                                                                                                                                                                                                                                                                                                                 June 26, 2024 | [Read Online]( Rivian partners with VW, stock is up big In partnership with Good day, 360 — These setups look primed! Please join us ALL DAY today in our biggest trading room — [Market Masters](. Be the best prepared trader on the Street! FOCUS LIST🔎 WENA - Up over 75% in the pre-market after securing key patent in Europe for Human Klotho Gene RNA Slice Variant and Protein RIVN - Up over 30% in pre after announcing a joint venture and $5billion investment by VW SVRA - Up over 30% in pre after Phase 3 trial success in treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Jason Bond Picks - Penny Stocks When You Need a Bigger Boat: First World Problems Jason Bond Picks lighting it UP right now – [Get in there for a one-time $297 life of service!]( About 44 seats remain. HOTLIST🔥 WENA - Up over 75% in the pre-market after securing key patent in Europe for Human Klotho Gene RNA Slice Variant and Protein ANEW MEDICAL INC. (WENA) focuses on developing biologic medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. In the pre-market this morning, the [company announced]( that it had secured a key patent in Europe for Human Klotho Gene RNA Slice Variant and Protein. It has been granted and issued a patent in Europe, EP3377091B1, for the use of ANEW’s secreted Klotho gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases. ANEW is set to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest It has an exclusive, worldwide intellectual property licensed from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain. The stock traded up over 75% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $4.31. Beyond that, $5, $5.50, $6, $6.50 and $7 come into play. Below $4.31, targets to the downside are $4, $3.50, $3, $2.50, $2 and then a gap fill at $1.65. RIVN - Up over 30% in pre after announcing a joint venture and $5billion investment by VW  Rivian Automotive Inc. (RIVN) together with its subsidiaries, designs, develops, manufactures, and sells electric vehicles and accessories. In the after-hours yesterday, the [company announced]( that they would enter a joint venture with Volkswagen Group(VW) to develop software defined vehicle (SDV) platforms to be used for both companies’ future electric vehicles. VW would invest an initial US$1bn in Rivian with up to $4bn in planned additional investment for a total expected deal size of $5bn. The JV was expected to "build on Rivian’s industry leading software and electrical architecture to create a best in class, software defined vehicle technology platform". The stock traded up over 30% in the pre-market in reaction to the news. The $16 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $17, $18 and then the after-hours high at $18.88. Beyond that, $19, $20 and $21 come into play. Below $16, targets to the downside are $15.77, $15, $14, $13.50 and $13. *sponsored by World Copper Copper is up 70% Discover the Zonia Advantage - Up to 4x faster to revenues vs. typical mines - 1-Billion lbs+ of Copper in global copper inventory - Copper +70% over last 5 years [LEARN MORE]( [(OTC: WCUFF | TSX.V: WCU)]( SVRA - Up over 30% in pre after Phase 3 trial success in treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Savara Inc. (SVRA) is a clinical stage biopharmaceutical company that focuses on rare respiratory diseases. In the pre-market this morning, the [company announced]( that its Molgramostim Nebulizer Solution (Molgramostim) achieved statistical significance for primary endpoint and multiple secondary endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Highlights include: Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George’s Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 The stock traded up over 30% in the pre-market in reaction to the news. The first target to the upside is resistance around the $5.20 area. Above that, targets are $5.50 and then the pre-market high at $6.25. Beyond that, $6.50, $7, $7.50 and $8 come into play. Below $5.20, targets to the downside are $5, $4.65, $4.50, $4.20, $4.05, $3.90 and then a gap fill at $3.80. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](